

Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets

Market Research Report | 2023-10-13 | 131 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The scope of the report includes biologics CDMO services, industries, initiatives, patents, and companies. The markets for biologics CDMO are given for 2020, 2021, 2022, 2023 and 2028.

This report explains why biologics CDMO is important in pharmaceutical and biotechnology industry. It then discusses some of the significant research initiatives that are impacting biologics CDMO. The main market-driving forces are also discussed.

The report examines the markets by product type, cell line type and region. The report provides market data and forecasts for biologics CDMO by product type, including biologics and biosimilars. The specific regional markets covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW).

In the report BCC Research summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022.

Report Includes:

- 40 data tables and 10 additional tables
- An up-to-date overview and industry analysis of the global markets for biologics contract development and manufacturing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

organizations (CDMO)

- Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Estimation of the actual market size and revenue forecast for biologics CDMO market in USD million values, and their corresponding market share analysis based on the product type, cell line type, and geographic region
- In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of macroeconomic variables on biologics CDMO marketplace
- Discussion of ESG developments in global CDMO services market, with emphasis on importance of ESG, consumer attitudes, risks and opportunity assessment, and ESG followed practices
- Identification of the pharma companies that are considered as leaders in their field, as well as technological means these companies are using to exploit their markets and dominate the market in their fields
- Market outlook and opportunity assessment of the industry structure for biologics CDMO services, and evaluation of ongoing clinical trials and R&D activities estimating current and future market demand
- Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
- Analysis of the company competitive landscape based on recent developments, key financials, and operational integration
- Company profiles of major players within the industry, including Lonza Group, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim, and Catalent Inc.

Executive Summary

Summary:

Contract development and manufacturing organizations serve the pharmaceutical industry and provide clients with services such as drug development, process development, analytical testing, formulation development, scale-up, manufacturing, packaging and distribution. These services can be provided on a standalone basis or as part of an end-to-end service offering.

A biologics contract development and manufacturing organization (CDMO) provides pharmaceutical companies with biological medical product development and manufacturing services. This type of CDMO may either specialize in developing and manufacturing biologics alone, or may offer these same services for biologics and small molecule drugs. Biologics is a general term for drugs manufactured using biotechnology. Unlike small-molecule drugs chemically manufactured, biologics are complex molecules, such as proteins or cells used as medicinal ingredients.

When a pharmaceutical company discovers a new medical biologic, it may choose to partner with a biologics CDMO to outsource one or more steps of the development and manufacturing process. Some biologics CDMOs focus on supporting certain parts of the development process, while full-service biologics CDMOs have the capability to handle each stage of drug development and manufacturing. Biologics CDMOs are valuable resources for pharmaceutical companies, as they have extensive experience navigating everything from pre-formulation to clinical trials and commercial production.

The global biologics CDMO market was valued at nearly \$REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach \$REDACTED billion by the end of 2028. Growth in this market is fueled by the increasing R&D activities, prevalence of chronic diseases, rising demand for biologics, increasing aging populations, continuing investment in healthcare infrastructure, and the perpetual parade of new products.

In this report, the global market for biologics CDMO is segmented into product type, cell line type and geographic region. Product types include biologics and biosimilars.

Biologics CDMO companies are concentrating on pharmaceutical and biotechnology companies to provide services for drug

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

development. For instance, in April 2022, ChimeronBio signed a manufacturing agreement with FujiFilm Diosynth Biotechnologies (FDB) to expand its oncology portfolio to include clinics. ChimeronBio selected FDB as its partner for transferring and scaling its drug substance manufacturing process.

The global market for biologics CDMO by cell line type is categorized into mammalian, microbial and other modalities. The mammalian segment is expected to increase from \$REDACTED billion in 2022 to \$REDACTED billion by the end of 2028, at a CAGR of REDACTED% for the period.

Table of Contents:

- Table of Contents
- Chapter 1 Introduction
 - Study Goals and Objectives
 - Reasons for Doing This Study
 - Scope of Report
 - Methodology
 - Information Sources
 - Geographic Breakdown
- Chapter 2 Summary and Highlights
 - Market Outlook
 - Market Summary
- Chapter 3 Market Overview
 - Introduction
 - Benefits of Biologics CDMOs
 - Expertise
 - Equipment and Manufacturing Facilities
 - Scalability
 - Benefits of Outsourcing
 - Drawbacks to Outsourcing
 - Contract Manufacturing
 - Types of Contract Manufacturers
 - Evolution of Contract Manufacturing Organizations
 - Outsourcing
 - Criteria for Evaluating a Contract Manufacturer
 - Core Capabilities of CMOs
 - Core Functional Areas Requiring Constant Attention
 - Criteria for Selecting an Outsourcing Partner
 - Top Sources of Dissatisfaction
 - Challenges in Contract Manufacturing
 - Services Offered by CMOs
 - Contract Research
 - Selecting a CRO
 - Services Offered by CROs
 - Checklist for Selecting a CRO
 - Benefits of Using a CRO
 - Client/CRO Relationship
- Chapter 4 Market Dynamics
 - Market Drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rising Prevalence of Cancer
Increasing Demand for Biologics
Rising Use of CDMOs
Increasing Elderly Population
Market Restraints
Biologic Product Costs and Price Controls
Capacity Constraints
Manufacturing Costs
Market Opportunities
Co-development of Biosimilars
Chapter 5 Global Market for Biologics CDMOs by Product Type
Introduction
Biologics
Biosimilars
Biologics
Biosimilars
Chapter 6 Global Market for Biologics CDMOs by Cell-Line Type
Mammalian
Microbial (Non-mammalian)
Other Modalities
Chapter 7 Global Market for Biologics CDMOs by Region
Market Overview and Discussion
North America
Europe
Asia-Pacific
RoW
Chapter 8 Sustainability in Biologics CDMOs: An ESG Perspective
Introduction to ESG
Sustainability in Biologics CDMO Industry: An ESG Perspective
Key ESG Issues
Attitudes toward ESG
Industry ESG Performance Analysis
Toyobo and ESG
Concluding Remarks from BCC Research
Chapter 9 Emerging Technologies and Developments
Overview
Big Data, AI and ML
Single-use Technology
Process Analytical Technology (PAT)
Chapter 10 Regulatory Landscape
Regulation of Biologics Services
FDA Regulations
European Regulations
Impact of FDA Regulations
The Declaration of Helsinki
CDISC Standards
Chapter 11 M&A and Venture Funding Outlook

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

M&A Analysis
Recent News
Chapter 12 Competitive Intelligence
Chapter 13 Company Profiles
ABBVIE PHARMACEUTICAL CONTRACT MANUFACTURING
AGC BIOLOGICS
BOEHRINGER INGELHEIM BIOXCELLENCE
BINEX CO. LTD.
BIOVIAN OY
BORA PHARMACEUTICAL CDMO
CATALENT INC
CYTOVANCE BIOLOGICS
EMERGENT BIOSERVICES
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
ICON PLC
JRS PHARMA GMBH & CO. KG
KEMWELL
LONZA GROUP
LOTTE BIOLOGICS
PAREXEL INTERNATIONAL CORP.
RENTSCHLER BIOPHARMA SE
SAMSUNG BIOLOGICS
SANDOZ INTERNATIONAL GMBH
THERMO FISHER SCIENTIFIC INC.
TOYOBO CO. LTD.
WUXI XDC
Chapter 14 Appendix

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets

Market Research Report | 2023-10-13 | 131 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

